Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Net Cash Flow (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Net Cash Flow for 7 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 1188.89% year-over-year to $4.1 million, compared with a TTM value of -$1.0 million through Dec 2025, up 91.45%, and an annual FY2025 reading of -$1.0 million, up 91.45% over the prior year.
  • Net Cash Flow was $4.1 million for Q4 2025 at aTYR PHARMA, up from -$11.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $57.6 million in Q3 2021 and bottomed at -$57.4 million in Q4 2021.
  • Average Net Cash Flow over 5 years is -$198700.0, with a median of -$349500.0 recorded in 2024.
  • The sharpest move saw Net Cash Flow plummeted 4687.82% in 2021, then soared 2375.39% in 2025.
  • Year by year, Net Cash Flow stood at -$57.4 million in 2021, then soared by 87.02% to -$7.5 million in 2022, then soared by 271.63% to $12.8 million in 2023, then tumbled by 102.96% to -$378000.0 in 2024, then soared by 1188.89% to $4.1 million in 2025.
  • Business Quant data shows Net Cash Flow for ATYR at $4.1 million in Q4 2025, -$11.2 million in Q3 2025, and $7.3 million in Q2 2025.